PMID- 38413637 OWN - NLM STAT- MEDLINE DCOM- 20240229 LR - 20240301 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Feb 27 TI - Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national survey study. PG - 4785 LID - 10.1038/s41598-024-54886-0 [doi] LID - 4785 AB - The coronavirus disease 2019 (COVID-19) pandemic has been a major challenge worldwide for the past years with high morbidity and mortality rates. While vaccination was the cornerstone to control the pandemic and disease spread, concerns regarding safety and adverse events (AEs) have been raised lately. A cross-sectional study was conducted between January 1st and January 22nd, 2022, in six Arabic countries namely Saudi Arabia, Egypt, Syria, Libya, Iraq, and Algeria. We utilized a self-administered questionnaire validated in Arabic which encompassed two main parts. The first was regarding sociodemographic data while the second was about COVID-19 vaccination history, types, doses, and experienced AEs. A multistage sampling was employed in each country, involving the random selection of three governorates from each country, followed by the selection of one urban area and one rural area from each governorate. We included the responses of 1564 participants. The most common AEs after the first and second doses were local AEs (67.9% and 46.6%, respectively) followed by bone pain and myalgia (37.6% and 31.8%, respectively). After the third dose, the most common AEs were local AEs (45.7%) and fever (32.4%). Johnson and Johnson, Sputnik Light, and Moderna vaccines showed the highest frequency of AEs. Factors associated with AEs after the first dose included an increase in age (aOR of 61-75 years compared to the 12-18 years group: 2.60, 95% CI: 1.59-4.25, p = 0.001) and male gender (OR: 0.72, 95% CI: 0.63-0.82, p < 0.001). The cumulative post-vaccination COVID-19 disease was reported with Sinovac (16.1%), Sinopharm (15.8%), and Johnson and Johnson (14.9) vaccines. History of pre-vaccination SARS-CoV-2 infection significantly increases the risk of post-vaccination COVID-19 after the first, second, and booster doses (OR: 3.09, CI: 1.9-5.07, p < 0.0001; OR: 2.56, CI: 1.89-3.47, p < 0.0001; and OR: 2.94, CI: 1.6-5.39, p = 0.0005 respectively). In conclusion, AEs were common among our participants, especially local AEs. Further extensive studies are needed to generate more generalizable data regarding the safety of different vaccines. CI - (c) 2024. The Author(s). FAU - Amer, Samar A AU - Amer SA AUID- ORCID: 0000-0002-9475-6372 AD - Department of Public Health and Community Medicine, Faculty of Medicine, Zagzig University, Zagazig, Egypt. dr_samar11@yahoo.com. AD - Membership at the Royal Colleague of General Practitioners [INT], London, UK. dr_samar11@yahoo.com. AD - Department of Mental Health Primary Care, Nova University, Lisbon, Portugal. dr_samar11@yahoo.com. FAU - Al-Zahrani, Ali AU - Al-Zahrani A AD - Research and Innovation Group, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - Imam, Esraa A AU - Imam EA AD - Department of Family Medicine, Faculty of Medicine, MOH, Riyadh, Saudi Arabia. FAU - Ishteiwy, Ehab M AU - Ishteiwy EM AUID- ORCID: 0000-0002-6476-1437 AD - Internship Year at Albayda Medical Center (AMC), Omar-Almukhtar University, Albayad, Libya. FAU - Djelleb, Ines F AU - Djelleb IF AUID- ORCID: 0000-0002-6241-0895 AD - Faculty of Medicine, Badji Mokhtar, 23000, Annaba, Algeria. FAU - Abdullh, Lina R AU - Abdullh LR AUID- ORCID: 0000-0002-4050-193X AD - Department of Dermatology, Faculty of Medicine, University of Baghdad, Baghdad, Iraq. FAU - Ballaj, Dana AU - Ballaj D AUID- ORCID: 0000-0001-5505-4397 AD - Faculty of Medicine, University of Aleppo, Aleppo, Syria. FAU - Amer, Youmna A AU - Amer YA AD - Department of Rheumatology and Rehabilitation, Faculty of Medicine, Zagzig University, Zagazig, Egypt. FAU - El-Sokkary, Rehab H AU - El-Sokkary RH AUID- ORCID: 0000-0002-8135-7671 AD - Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Elshabrawy, Arafa M AU - Elshabrawy AM AD - Endocrinology and Diabetes Division, Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt. FAU - Eskander, Georgette AU - Eskander G AD - Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. FAU - Shah, Jaffer AU - Shah J AD - Weill Cornell Medicine, New York, NY, USA. FAU - Raza, Muhammad Liaquat AU - Raza ML AUID- ORCID: 0000-0003-4487-5223 AD - Al Fatima Hospital, Karachi, Pakistan. FAU - ALsafa, Abdulaziz Majed A Aba AU - ALsafa AMAA AD - Specialist Nursing, Ministry of Health, Riyadh, Saudi Arabia. FAU - Ali, Hossam Tharwat AU - Ali HT AUID- ORCID: 0000-0001-8077-5911 AD - Qena Faculty of Medicine, South Valley University, Qena, 83621, Egypt. Hossam.Tharwat@med.svu.edu.eg. FAU - Fawzy, Hebatallah M AU - Fawzy HM AD - Lecturer of Public Health and Community Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt. LA - eng PT - Journal Article DEP - 20240227 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) SB - IM MH - Male MH - Humans MH - Middle Aged MH - Aged MH - COVID-19 Vaccines/adverse effects MH - Arabs MH - Cross-Sectional Studies MH - *COVID-19/epidemiology/prevention & control MH - SARS-CoV-2 MH - *Drug-Related Side Effects and Adverse Reactions MH - Vaccination/adverse effects PMC - PMC10899622 OTO - NOTNLM OT - Adverse effects OT - Arab Populations OT - COVID-19 OT - Coronavirus OT - SARS-CoV-2 OT - Vaccination COIS- The authors declare no competing interests. EDAT- 2024/02/28 00:43 MHDA- 2024/02/29 06:42 PMCR- 2024/02/27 CRDT- 2024/02/27 23:32 PHST- 2023/12/02 00:00 [received] PHST- 2024/02/17 00:00 [accepted] PHST- 2024/02/29 06:42 [medline] PHST- 2024/02/28 00:43 [pubmed] PHST- 2024/02/27 23:32 [entrez] PHST- 2024/02/27 00:00 [pmc-release] AID - 10.1038/s41598-024-54886-0 [pii] AID - 54886 [pii] AID - 10.1038/s41598-024-54886-0 [doi] PST - epublish SO - Sci Rep. 2024 Feb 27;14(1):4785. doi: 10.1038/s41598-024-54886-0.